Voltron Therapeutics
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
575 5th Ave Fl 14, New York City, New Yo...Phone Number
(212) 953-4936Website
www.voltrontx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Voltron Therapeutics
Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of the company's world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers).Explore more
Popular SearchesVoltron Therapeutics IncVoltron TherapeuticsSIC Code 87,873NAICS Code 54,541Show moreVoltron Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Voltron Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Voltron Therapeutics
Click to see if Voltron Therapeutics had a recent Job posting/layoffs
Check if Voltron Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Voltron Therapeutics has new funding data
Voltron Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Voltron Therapeutics launches new products
Earning: See what the market has to say on Voltron Therapeutics recently announced quarterly report
Check out if Voltron Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Voltron Therapeutics
Compare insights from companies similar to Voltron Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
1989
JC
Joseph CotropiaChief Scientific Officer and Board of Directors of Enzolytics, Inc.
Company Profile Activity
Activity Insights
Voltron Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Voltron Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Voltron Therapeutics.
Voltron Therapeutics Tech Stack
A closer look at the technologies used by Voltron Therapeutics
See more technologies
Voltron Therapeutics News & Media
Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen
Vaccine was shown to induce immunity against Prostate Stem Cell Antigen (PSCA) previously Full protein targeting expands the Self-Assembling Vaccine (SAV) platform's potential targets NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company,...Lucius Partners Portfolio Company Voltron Therapeutics, Inc Adds of Manufacturing Expert to Scientific Advisory Board
Globally recognized manufacturing and product supply expert Tibor Nemes joins Scientific Advisory Board NEW YORK, NY, UNITED STATES, September 14, 2023 /EINPresswire.com/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today …Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial
Self Assembling Vaccine will target Prostate Stem Cell Antigen (PSCA) Key target in Prostate, Renal and Urothelial Cancers NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc, a Lucius Partners portfolio company, announced today that it has signed a new Sponsored Research...Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium
Poster demonstrates the utility of Voltron's Self-Assembling Vaccine platform in Pandemic Preparedness and Immuno-Oncology NEW YORK, Oct. 26, 2022 /PRNewswire/ -- Voltron Therapeutics, a Lucius Partners portfolio company, announced the company's poster on its proprietary Self-Assembling...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Voltron Therapeutics
Sign Up For FreeTo access detailed company insights
Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusiv... Read More
